https://doi.org/10.55788/b5380e78
The Molecular International Prognostic Scoring System for myelodysplastic syndromes (IPSS-M) added molecular parameters into the prognostication for MDS [1,2]. However, since only 9% of the patients in the cohort of the study by Bernard et al. underwent HSCT, the applicability of the IPSS-M in the context of transplantation is unclear. Dr Carmelo Gurnari (Cleveland Clinic, OH, USA & Tor Vergata University, Italy) and co-investigators conducted a real-world study among 416 participants with MDS to evaluate the value of IPSS-M in transplantated patient. In the study cohort, 36% of the participants underwent the transplant upfront, and in 85% of treated cases, hypomethylating agents were given as bridge therapy.
The Revised International Prognostic Scoring System (IPSS-R), which uses haematological and cytogenetic instead of molecular parameters, stratified participants according to risk: very low (6%), low (17%), intermediate (19%), high (26%), and very high (32%) risk. The calculated IPSS-M scores resulted in a significant redistribution of participants with respect to these risk categories: very low (27%), low (18%), moderately low (14%), moderately high (15%), high (10%), and very high (16%). Furthermore, the c-index for overall survival was 0.583 for the IPSS-M and 0.547 for the IPSS-R, suggesting that the IPSS-M is slightly better at predicting OS outcomes than the IPSS-R. The c-index of IPSS-M for OS was lower than the observed c-indexes in the study by Bernard et al. and comparable with existing specific HSCT MDS risk scores [3].
The authors concluded that molecular data adds value to the prognostication of patients with MDS undergoing HSCT. Dr Gurnari argued that the lower c-indexes that were reported in the current study, as compared with the original IPSS-M study by Bernard et al., point out that there are transplant-related factors to consider beyond disease-specific variables and molecular information.
- Gurnari C, et al. Outcome prediction in patients with myelodysplastic syndrome undergoing hematopoietic cell transplant in the molecular era of IPSS-M. OS17-05, European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting, 23–26 April 2023, Paris, France.
- Gurnari C, et al. Leukemia. 2023;37(3):717–719.
- Bernard E, et al. N Engl J Med Evid. 2022;1(7).
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Next-generation cell therapies for cancer: CAR-NK cells Next Article
Long-term success for CD19 CAR T-cell therapy in CLL »
« Next-generation cell therapies for cancer: CAR-NK cells Next Article
Long-term success for CD19 CAR T-cell therapy in CLL »
Table of Contents: EBMT 2023
Featured articles
CAR T cells rise to the front in multiple myeloma
Acute Leukaemia
Quizartinib plus chemotherapy improves OS in patients with AML undergoing ASCT
Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT
Is ASCT a reasonable option in patients with invasive aspergillosis?
Tacrolimus versus cyclosporine A in AML
Promising novel target identified for AML
Multiple Myeloma
Ide-cel superior to standard therapies in triple-class exposed RRMM
ASCT or CAR T cell as first-line therapy for MM?
DETERMINATION: Does one size fit all in multiple myeloma?
Graft-Versus-Host Disease
New options to treat steroid-refractory chronic GvHD
New developments in steroid-refractory acute GvHD
Miscellaneous Topics
Long-term success for CD19 CAR T-cell therapy in CLL
Can molecular data improve prognostication in MDS patients undergoing HSCT?
Next-generation cell therapies for cancer: CAR-NK cells
Novel drugs and strategies around ASCT for Hodgkin lymphoma
Thalassaemia: Advances in conventional transplantation and gene therapy
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy